Xilio Therapeutics annual depreciation and amortization
2020
2021
2022
2023
2024
2025
Xilio Therapeutics Depreciation & Amortization Growth & History (XLO)
Xilio Therapeutics's depreciation and amortization was $1.5M for fiscal 2025.
View full Xilio Therapeutics company overviewXilio Therapeutics annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $1.5M | −$103,000 | −6.27% |
| 2024 | 2024-12-31 | $1.6M | −$256,000 | −13.47% |
| 2023 | 2023-12-31 | $1.9M | $53,000 | +2.87% |
| 2022 | 2022-12-31 | $1.8M | $348,000 | +23.22% |
| 2021 | 2021-12-31 | $1.5M | $434,000 | +40.75% |
| 2020 | 2020-12-31 | $1.1M | — | — |
Xilio Therapeutics quarterly depreciation and amortization
Q1.21
Q2.21
Q3.21
Q1.22
Q2.22
Q3.22
Q1.23
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Depreciation and amortization | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $331,000 | −$50,000 | −13.12% |
| Q1 2026 | 2026-03-31 | $344,000 | −$153,000 | −30.78% |
| Q4 2025 | 2025-12-31 | $323,000 | — | — |
| Q3 2025 | 2025-09-30 | $340,000 | −$40,000 | −10.53% |
| Q2 2025 | 2025-06-30 | $381,000 | −$64,000 | −14.38% |
| Q1 2025 | 2025-03-31 | $497,000 | $54,000 | +12.19% |
| Q3 2024 | 2024-09-30 | $380,000 | −$80,000 | −17.39% |
| Q2 2024 | 2024-06-30 | $445,000 | −$47,000 | −9.55% |
| Q1 2024 | 2024-03-31 | $443,000 | −$56,000 | −11.22% |
| Q3 2023 | 2023-09-30 | $460,000 | −$13,000 | −2.75% |
| Q2 2023 | 2023-06-30 | $492,000 | $47,000 | +10.56% |
| Q1 2023 | 2023-03-31 | $499,000 | $59,000 | +13.41% |
| Q3 2022 | 2022-09-30 | $473,000 | $91,000 | +23.82% |
| Q2 2022 | 2022-06-30 | $445,000 | $72,000 | +19.30% |
| Q1 2022 | 2022-03-31 | $440,000 | $90,000 | +25.71% |
| Q3 2021 | 2021-09-30 | $382,000 | — | — |
| Q2 2021 | 2021-06-30 | $373,000 | — | — |
| Q1 2021 | 2021-03-31 | $350,000 | — | — |
Xilio Therapeutics depreciation and amortization trends
Over the last five fiscal years, Xilio Therapeutics's depreciation and amortization increased from $1.1M to $1.5M, a change of $476,000. The latest reported quarter, Q2 2026, shows $331,000.
About the metric
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Calculation and source
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Xilio Therapeutics source filings ↗